Switch theme
Sign up to access all valuation multiples
Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.
2000
n/a
LTM Revenue n/a
LTM EBITDA n/a
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hebei Changshan has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hebei Changshan achieved revenue of $194M and an EBITDA of -$146M.
Hebei Changshan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hebei Changshan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $194M | n/a | XXX | XXX | XXX |
| Gross Profit | $238M | $143M | XXX | XXX | XXX |
| Gross Margin | 122% | NaN% | XXX | XXX | XXX |
| EBITDA | -$146M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -75% | NaN% | XXX | XXX | XXX |
| Net Profit | $32.2M | $2.4M | XXX | XXX | XXX |
| Net Margin | 17% | NaN% | XXX | XXX | XXX |
| Net Debt | $141M | $179M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hebei Changshan's stock price is CNY 20 (or $3).
Hebei Changshan has current market cap of CNY 18.6B (or $2.6B), and EV of CNY 20.7B (or $2.8B).
See Hebei Changshan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.6B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hebei Changshan has market cap of $2.6B and EV of $2.8B.
Hebei Changshan's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Hebei Changshan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hebei Changshan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHebei Changshan's NTM/LTM revenue growth is n/a
Hebei Changshan's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hebei Changshan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hebei Changshan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hebei Changshan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hebei Changshan acquired XXX companies to date.
Last acquisition by Hebei Changshan was XXXXXXXX, XXXXX XXXXX XXXXXX . Hebei Changshan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hebei Changshan founded? | Hebei Changshan was founded in 2000. |
| Where is Hebei Changshan headquartered? | Hebei Changshan is headquartered in China. |
| Is Hebei Changshan publicy listed? | Yes, Hebei Changshan is a public company listed on SHE. |
| What is the stock symbol of Hebei Changshan? | Hebei Changshan trades under 300255 ticker. |
| When did Hebei Changshan go public? | Hebei Changshan went public in 2011. |
| Who are competitors of Hebei Changshan? | Similar companies to Hebei Changshan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hebei Changshan? | Hebei Changshan's current market cap is $2.6B |
| Is Hebei Changshan profitable? | Yes, Hebei Changshan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
